Key Takeaways
Cencora (formerly AmerisourceBergen, rebranded August 2023) delivered fiscal year 2025 (ended September 30, 2025) results that validated pharmaceutical distribution as one of the most durable businesses in the US economy — a toll-booth model on the flow of approximately $600-650B in annual US pharmaceutical spending, generating revenue of approximately $320-340B (growing approximately 10-13% from FY2024's approximately $293B) with adjusted EBITDA of approximately $3.6-4.0B at approximately 1.1-1.2% margins and adjusted EPS of approximately $16.00-18.00, growing approximately 12-15% as volume growth compounded with mix shift toward higher-margin specialty pharmaceuticals and aggressive share repurchases reduced the diluted share count by approximately 3-4% annually. The GLP-1 revolution — Ozempic, Wegovy, Mounjaro, Zepbound moving from niche diabetes treatments to mainstream obesity drugs prescribed to tens of millions of Americans — was the most important single product category tailwind in FY2025, with GLP-1 distribution volumes growing approximately 60-80% as Cencora's pharmacy and specialty distribution networks became the primary logistics layer for the category's explosive growth. Specialty pharmaceutical distribution — oncology drugs through ION Solutions, rare disease biologics, biosimilars — represented approximately 38-42% of adjusted gross profit despite being a smaller share of total revenue, because specialty drugs carry margins of approximately 6-10% versus approximately 1-2% for commodity generic distribution. The FY2026 thesis is the intersection of structural tailwinds: GLP-1 volume growth moderating from hypergrowth to sustained 25-35% annually as the prescribing base matures, biosimilar penetration accelerating as reference biologic patents expire, and Cencora's Alliance Healthcare European operation recovering from FY2023-FY2024 integration headwinds to deliver the synergies originally targeted — a combination that supports low-double-digit EPS growth and multiple re-rating as the opioid settlement liability becomes a smaller portion of enterprise value.
Cencora was founded as Bergen Brunswig in 1888 and grew through a century of pharmaceutical distribution consolidation, merging with AmeriSource in 2001 to become AmerisourceBergen — one of the "Big Three" drug distributors alongside McKesson and Cardinal Health that collectively handle approximately 90% of US pharmaceutical distribution. The 2021 acquisition of Alliance Healthcare ($6.5B) expanded Cencora into European pharmaceutical distribution and logistics. CEO Robert Mauch, who succeeded Steven Collis in 2023, inherited a business in the midst of both the Alliance integration and the GLP-1 wave — managing rapid volume growth in a distribution business where operational efficiency, working capital management, and the speed of claim processing directly translate to returns on equity.
Business Structure
Cencora operates two primary segments built around the pharmaceutical supply chain.
US Healthcare Solutions (~92% of revenue, ~$295-315B): Distributes pharmaceutical products — branded, generic, specialty, and biosimilar — to approximately 60,000+ pharmacies (retail chains, independent pharmacies, mail order), approximately 40,000+ physician practices and clinics, and approximately 3,500+ hospital systems. Within US Healthcare, the key sub-businesses are: drug distribution to retail pharmacy (largest by volume, lowest margin), specialty distribution through ION Solutions and Oncology Supply (oncology practices, approximately 5,000+ US oncologists are ION customers), and other specialty logistics (World Courier, specialty cold-chain). US Healthcare generates the large majority of segment profit despite razor-thin distribution margins because of scale: Cencora handles approximately 1.5-2.0 million pharmaceutical transactions daily.
International Healthcare Solutions (~8% of revenue, ~$25-30B): Alliance Healthcare operations across UK, Germany, Spain, France, Portugal, and other European markets, providing pharmaceutical distribution, logistics, and direct-to-patient services. Alliance was acquired to diversify revenue geography and capture the faster-growing European specialty pharmaceutical market, but the integration was complex and FY2023-FY2024 margins lagged original projections.
Key Core Metrics Performance
Revenue and EPS Trajectory (FY2020–FY2025)
| Fiscal Year (ends Sep 30) | Revenue | Adj. EBITDA | Adj. EBITDA Margin | Adj. Diluted EPS |
|---|---|---|---|---|
| FY2020 | $189.9B | ~$2.6B | ~1.37% | ~$8.38 |
| FY2021 | $213.5B | ~$2.8B | ~1.31% | ~$9.26 |
| FY2022 | $238.6B | ~$2.9B | ~1.22% | ~$10.77 |
| FY2023 | $262.2B | ~$3.2B | ~1.22% | ~$13.22 |
| FY2024 | ~$293.0B | ~$3.4B | ~1.16% | ~$14.82 |
| FY2025 | ~$328.0B | ~$3.8B | ~1.16% | ~$17.00 |
Revenue growth of approximately 12% in FY2025 reflects the GLP-1 volume contribution: Cencora handles distribution for Novo Nordisk and Eli Lilly's weight-loss drugs, and as prescription volumes tripled over FY2023-FY2025, distribution revenue from this category alone contributed approximately $8-12B of incremental revenue annually.
GLP-1 Distribution Volume Impact (FY2023–FY2025)
| Fiscal Year | GLP-1 Distribution Revenue (est.) | YoY Growth | % of US Revenue |
|---|---|---|---|
| FY2023 | ~$18B | — | ~7% |
| FY2024 | ~$35B | +94% | ~13% |
| FY2025 | ~$58B | +66% | ~19% |
GLP-1 approaching 20% of US Healthcare revenue is a meaningful concentration — but also a durable tailwind, as the prescribing base expansion has years of runway remaining (approximately 70M Americans meet clinical criteria for GLP-1 therapy, versus approximately 15-20M currently treated). Distribution margin on GLP-1s is approximately equal to branded drug distribution generally (~1.5-2.0% of revenue) — the volume scale is what drives the EPS contribution.
Specialty vs. Commodity Drug Mix (FY2022–FY2025)
| Fiscal Year | Specialty Adj. Gross Profit % | Generic/Commodity % | Specialty Revenue % |
|---|---|---|---|
| FY2022 | ~35% | ~65% | ~22% |
| FY2023 | ~37% | ~63% | ~24% |
| FY2024 | ~39% | ~61% | ~26% |
| FY2025 | ~41% | ~59% | ~28% |
Each percentage point shift from commodity to specialty distribution adds approximately 20-25 basis points to blended gross margin and approximately $0.20-0.25/share to adj. EPS at constant tax and share count.
Share Repurchase and EPS Leverage (FY2021–FY2025)
| Fiscal Year | Diluted Shares | YoY Change | Buybacks |
|---|---|---|---|
| FY2021 | ~212M | — | ~$1.0B |
| FY2022 | ~207M | -2.4% | ~$1.5B |
| FY2023 | ~204M | -1.4% | ~$1.5B |
| FY2024 | ~199M | -2.5% | ~$2.0B |
| FY2025 | ~193M | -3.0% | ~$2.3B |
Cencora has reduced diluted share count by approximately 9% over four years while growing EPS approximately 80% — the compounding of volume growth, specialty mix improvement, and buybacks in a capital-light distribution business.
Market Evaluation
Cencora trades at approximately 20-25x forward adjusted EPS — a modest premium to the S&P 500 average that understates the quality of the earnings stream: pharmaceutical distribution revenue is approximately 95% recurring (customers must continue replenishing drugs), pricing is stable (regulated fee-for-service plus formulary management), and the Big Three's oligopoly position means new entrants cannot scale without the relationships with manufacturers, health systems, and pharmacy chains that took decades to build. The bull case is compounding EPS growth: Cencora's approximately 12-15% annual EPS growth combining low-single-digit volume expansion, mix shift, and buybacks at 20x earnings implies approximately 15% total return annually without multiple expansion — a high-quality compounder. The bear case is drug pricing reform: if the Inflation Reduction Act's drug pricing negotiation provisions expand to more drugs and compress branded drug prices significantly, Cencora's distribution fees (typically calculated as a percentage of drug invoice price) would face structural headwinds — though this risk is partially mitigated by the shift to specialty drugs where fee-for-service models are more common than percentage-of-price.
GLP-1 Distribution Infrastructure and Biosimilar Wave
Cencora's GLP-1 distribution infrastructure — cold-chain storage, pharmacy delivery networks, specialty logistics — positioned it ahead of competitors for what became the fastest-growing pharmaceutical category in history. The logistics requirements of GLP-1 distribution are demanding: injectable medications require 2-8°C storage throughout the cold chain, high-volume single-dose pens require specialized packaging handling, and the rapid prescription growth created unprecedented demand spikes that tested every distribution network's capacity. Cencora's investment in cold-chain infrastructure and its deep relationships with specialty and retail pharmacy chains enabled it to capture approximately 33% of US GLP-1 distribution volume — roughly proportional to its overall pharmaceutical distribution market share, suggesting neither share gain nor loss versus the baseline.
The biosimilar wave is the next structural tailwind: as reference biologics (adalimumab/Humira, etanercept/Enbrel, bevacizumab/Avastin) lose exclusivity and biosimilar competition drives price declines of 40-70%, distribution volumes increase as dispensing rates rise with lower patient cost-sharing. Cencora's specialty distribution networks are the primary beneficiary: biosimilar distribution to physician practices and specialty pharmacies requires the same infrastructure as reference biologic distribution, and the volume expansion from lower-priced products more than offsets the per-unit margin compression. The combination of GLP-1 growth (high-price specialty, sustained), biosimilar expansion (high-volume specialty, growing), and Alliance Healthcare European recovery creates a multi-year EPS growth runway that makes Cencora's premium multiple durable.